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ABSTRACT
Background/aim To determine if overexpression of the
glaucoma gene MYOC is involved in the development of
open-angle glaucoma (OAG) and if its promoter variants
are associated with glaucoma in the Korean population.
Methods Human trabecular meshwork cells were
cultured in the presence of ophthalmic steroids such
as ﬂuorometholone, ﬂuorometholone acetate,
dexamethasone, prednisolone acetate and rimexolone.
The cells were cultured at a hydrostatic pressure of
32 mm Hg above atmospheric pressure and induction of
MYOC was evaluated by northern blot analysis. Genomic
DNA was extracted from blood samples obtained from
74 normal controls and 168 unrelated Korean patients
with OAG, including primary OAG, normal tension
glaucoma and steroid-induced glaucoma. A 461 base
pair (bp) DNA fragment of the MYOC promoter region
was ampliﬁed using PCR and its genotype was analysed
by directly sequencing the product.
Results The potencies of steroid eye drops in MYOC
induction in vitro was the same regardless of their
potential for elevating intraocular pressure in vivo.
Hydrostatic pressure had no effect on MYOC induction.
A dinucleotide repeat polymorphism and three single
nucleotide polymorphisms were identiﬁed, but no
obvious differences in the genotype distribution and allele
frequency of the variants between the control group and
any type of OAG were observed.
Conclusion Our data suggest that MYOC
overexpression is not a cause or an effect of intraocular
pressure elevation and that MYOC itself is not associated
with OAG.
INTRODUCTION
MYOC encodes a secretory glycoprotein of 504
amino acids named myocilin, and is the ﬁrst gene to
be linked to juvenile open-angle glaucoma (OAG)
and some forms of adult-onset primary open-angle
glaucoma (POAG).
1
The gene was identiﬁed as an upregulated mole-
cule in cultured trabecular meshwork (TM) cells
after treatment with dexamethasone (DEX) and was
originally referred to as trabecular meshwork-
inducible glucocorticoid response (TIGR).
2
It is well known that the long-term use of topical
ophthalmic steroids results in ocular hypertension
with glaucoma, known as steroid-induced glau-
coma (SIG), in up to 40% of the population.
3 SIG
mimics many aspects of POAG and both diseases
have been shown to be caused by elevated intra-
ocular pressure (IOP) due to decreased aqueous
outﬂow. Interestingly, the proﬁle of MYOC upre-
gulation by DEX is in a dose- and time-dependent
manner very similar to the course of development
of SIG.
2 This led many investigators to believe that
an increased MYOC level is a cause of glaucoma.
45
However, a putative association between MYOC
induction and OAG has not been ﬁrmly estab-
lished.
6e8
Determining whether or not MYOC expression
can cause glaucoma is important for understanding
the pathology of OAG for patients without muta-
tions in the MYOC coding region and for assessing
the risk of the disease with variants in the MYOC
non-coding region. Therefore, in the present study,
we investigated whether MYOC induction is
involved in the development of glaucoma. We
evaluated the potency of MYOC induction by
ophthalmic steroids with different abilities to
elevate IOP. We also investigated whether promoter
variants of MYOC are associated with glaucoma.
MATERIALS AND METHODS
Cell culture
Human trabecular meshwork (HTM) cells were
maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Life Technologies, Grand Island, New York,
USA) supplemented with 10% fetal bovine serum
and antibiotics at 378Ci nah u m i d i ﬁed 5%
CO2e95% air atmosphere. The cells, generously
provided by Paul L. Kaufman (University of
Wisconsin, Madison, Wisconsin, USA), were derived
from the normal eyes of a 27-year-old female donor.
Steroid treatment
HTM cells plated in 60-mm culture dishes were
grown to conﬂuence before addition of steroids. All
steroid eye drops (steroid ophthalmic suspensions)
were purchased from Alcon Pharmaceuticals (Fort
Worth, Texas, USA) and were prepared in phos-
phate buffered saline at 2.5 mM. Conﬂuent HTM
cells received doses of the diluted steroids and were
cultured for up to 9 days, and the media were
changed once every 3 days.
Hydrostatic pressure
Dishes with conﬂuent HTM cells were placed at
the bottom of a 2-l mass cylinder (Nalgen,
Rochester, New York, USA) in which fresh media
had been poured up to a height of 43 cm from the
bottom. The cells were cultured for 9 days in this
condition, which was equivalent to a hydrostatic
pressure of 32 mm Hg above atmospheric pressure.
Northern blot analysis
At the end of culture, the HTM cells were harvested
and total RNA was isolated. Approximately 5 mgo f
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Laboratory sciencetotalRNAwassize-fractionated,transferredtoanylonmembrane,
and then hybridised at658C overnight witha
32P-labelled probe for
human MYOC. After hybridisation, the membrane was washed
twice in 23 (sodium chloride/sodium citrate)SSC e0.1% (sodium
dodecyl sulfate)SDS and once in 13 SSCe0.1% SDS and was then
autoradiographed at 708C.
Blood samples
Peripheral blood samples were collected from 168 unrelated
Korean glaucoma patients who visited the Department of
Ophthalmology at Samsung Medical Center, Seoul, South
Korea. For inclusion of POAG, the patients had to meet the
following criteria. (1) An untreated mean IOP >21 mm Hg by
Goldmann applanation tonometry. (2) The anterior chamber
angles on gonioscopy were wide open. (3) The best corrected
visual acuity was 20/30 or better. (4) A typical glaucomatous
optic nerve appearance including focal or generalised narrowing
or disappearance of the neuroretinal rim, asymmetry in the cup
to disc ratio >0.2, disc haemorrhage or retinal nerve ﬁbre layer
defects. (5) A glaucoma hemiﬁeld defect corresponding to the
glaucomatous optic nerve damage detected in two consecutive
ﬁelds, at intervals of at least 2 months apart. Normal tension
glaucoma (NTG) was deﬁned as for POAG, except for untreated
mean IOP being #21 mm Hg by Goldmann applanation
tonometry. SIG was deﬁned as OAG associated with a high IOP
from administration of steroid eye drops for more than 2 weeks.
Blood samples from a control group of 74 normal healthy Korean
volunteers, unmatched for age or sex, were also obtained.
Genotyping
A 461 base pair (bp) DNA fragment of the 59-ﬂanking region of
MYOC, containing sequences from 396 bp upstream of the
transcriptional initiation site to 65 bp of the untranslated region,
was ampliﬁed from the genomic DNA by PCR with primers
designed based on available sequence data (GenBank accession
no. Z97171). The genotype distribution of polymorphisms was
determined by direct sequencing of the PCR product with the
terminator cycle-sequencing method using ﬂuorescent dideox-
ynucleotides and an automatic DNA sequencer (Applied
Biosystems, Foster City, California, USA). Statistical analysis
was performed using the Pearson c
2 test.
RESULTS
Effect of steroids and hydrostatic pressure on MYOC induction
Northern blot hybridisation revealed that the treatment of
conﬂuent HTM cells with DEX led to an apparent induction of
MYOC gene expression (ﬁgure 1B). This result demonstrates
that the HTM cells used in the present study were authentic
because steroid-induced MYOC induction has been observed
only in cultured TM cells or in TM tissues from perfused organ
cultures.
2 6
The exposure of HTM cells to steroid eye drops also led to
MYOC induction (ﬁgure 2). Treatment of cells with eye drops
containing increasing concentrations of ﬂuorometholone (Flucon),
ﬂuorometholone acetate (Flarex), DEX (Maxidex), prednisolone
acetate (Pred forte) and rimexolone (Vexol) all induced MYOC
expression in a dose-dependent manner. However, no differences
were observed in the potency of these drugs in terms of MYOC
induction. Time-course studies of MYOC induction also gave the
same results of no differences in the steady-state levels of MYOC
expressionatanytimepointsincellstreatedwithdifferentsteroids
(data not shown).
A hydrostatic pressure equivalent to 32 mm Hg above
atmospheric pressure appeared to affect the morphology of the
HTM cells (ﬁgure 1A). In addition to an increase in cell and
nuclear size, it was evident that the original partially elongated
shape changed to a rounder form. However, this morphological
change was not accompanied by any prominent induction of
MYOC (ﬁgure 1B).
Association of MYOC with glaucoma
Six alleles, ranging from 12 to 17 repeats of (G-T)n dinucleotides,
were found in the microsatellite that had previously been
described as being located 314 bp upstream from the translation
start site of MYOC.
2 Each allele was designated as (G-T)12 to (G-
T)17 according to the number of repeats. The genotype distri-
bution and allele frequencies of the (G-T)n microsatellite marker
Figure 1 Effect of hydrostatic pressure on morphology and induction of
MYOC expression in cultured human trabecular meshwork (HTM) cells.
(A) Phase-contrast images were photographed from cells cultured for
9 days in the absence (upper panel) or presence of a hydrostatic pressure
of 32 mm Hg above atmospheric pressure (lower panel). (B) RNA was
extracted from cells cultured in the absence (lane 1) or presence of
hydrostatic pressure (lane 3), hybridised with
32P-labelled MYOC cDNA,
and subjected to autoradiography (upper panel). The same RNA was
visualised by ethidium bromide staining (lower panel). Cells treated with
100 nM dexamethasone (DEX) (lane 2) served as a positive control.
Figure 2 Effect of ophthalmic steroids on the induction of MYOC
expression in cultured human trabecular meshwork (HTM) cells.
Conﬂuent HTM cells were cultured for 9 days in the presence of each
steroid eye drop at the indicated concentrations. All of the RNA was
extracted from each cell, hybridised with
32P-labelled MYOC cDNA, and
subjected to autoradiography (upper panel). RNA was also stained with
ethidium bromide as a loading control (lower panel).
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Laboratory sciencein normal control populations and patient populations are
summarised in table 1. Three alleles, (G-T)12,( G - T ) 16 and (G-
T)17, occurred so rarely that they were excluded from the anal-
ysis. The frequencies observed did not deviate signiﬁcantly from
those predicted by the HardyeWeinberg equilibrium. However,
there was no evidence of any differences in the genotype
distributions and allele frequencies between the glaucoma
groups and the control group.
In addition to the polymorphic microsatellites, we found
three single nucleotide polymorphisms (SNP), G-83A, T-224C
and G-306T, all of which have already been reported.
9 The
genotype distribution and allele frequencies of the SNPs in the
normal control group and patient groups are summarised in
table 2. SNP analyses also showed no evidence of association
between MYOC and glaucoma; none of the three SNP sites
showed an association with POAG, NTG or SIG.
DISCUSSION
Clinically, dexamethasone and prednisolone increase IOP more
frequently than ﬂuorometholone, hydrocortisone or rimex-
olone.
10 Fluorometholone in particular is less likely to increase
IOP. Rimexolone, which was recently introduced, also has a low
IOP-elevating potential that is comparable to that of ﬂuo-
rometholone in adults.
11 Nevertheless, eye drops with a low
IOP-elevating potential induced MYOC to the same extent as
eye drops with a high IOP-elevating potential. If MYOC
induction causes IOPelevation, the potency of MYOC induction
by an eye drop should correlate with the IOPelevation caused by
that drug. Therefore, our results suggest that MYOC induction
is not a cause of IOP elevation in SIG.
Clinically, ﬂuorometholone and dexamethasone are used at
a concentration of 0.1%, whereas prednisolone and rimexolone
are used at a concentration of 1%. Taking this into account, the
extent of MYOC induction by ﬂuorometholone or dexametha-
sone is 10 times less than that shown in ﬁgure 2. This further
suggests that MYOC induction is not primarily responsible for
steroid-induced IOP elevation.
MYOC induction in glaucomatous eyes might be the result,
rather than the cause, of IOP elevation. Initially, a clear induc-
tion of MYOC expression was seen in perfused human anterior
segments at high IOP.
12 However, no evidence of MYOC induc-
tion was obtained in combined tissues of rat iridocorneal angles,
despite IOP elevation.
13 In the present study, we cultured HTM
cells at a hydrostatic pressure of 32 mm Hg above atmospheric
pressure, which mimics an IOP >32 mm Hg in glaucoma
patients. This condition stressed the cells, as demonstrated by
apparent changes of cellular morphology, but did not lead to
MYOC expression, suggesting that it is not a secondary response
to IOP elevation. Previous studies have shown that there are no
prominent differences in the signal intensities for MYOC
expression between glaucomatous and non-glaucomatous eyes.
6
Furthermore, no signiﬁcant increase in MYOC expression was
observed in the TM of rats in a steroid-induced ocular hyper-
tension model, despite IOP elevation.
14 Together, these studies
support our results, arguing against the hypothesis that MYOC
induction could perhaps be considered part of a protective
response mechanism, rather than a homeostatic one.
12
In the 59-ﬂanking region of the MYOC, we found three bi-allelic
variants along with one dinucleotide repeat polymorphism, but
no association between the markers with any subtype of OAG.
This result was somewhat unexpected, because MYOC had been
considered to be a susceptibility gene for POAG.
1 Genetic studies
showed that alterations in the coding region of MYOC are asso-
ciated probably with a gain of pathogenic function rather than
a haplo-insufﬁciency in the pathogenesis of glaucoma.
15 16 This
fact can support the lack of association between POAG and
variants in the promoter region of the MYOC.I ti sa l s ou n c e r t a i n
whether the size of this study was large enough to detect any
association between the markers and POAG.
A possible association might be mediated either by a marker
itself or by other polymorphisms in linkage disequilibrium with
alleles of the marker. The lack of association between our
markers and OAG therefore implies no evidence that the
markers themselves are causative polymorphisms of OAG or
under linkage disequilibrium with other authentic poly-
morphisms or mutations in other regions of MYOC.N o
published results have deﬁnitively described MYOC promoter
mutations as a cause of glaucoma.
9 17e20 The T-153A poly-
morphism was reported to occur more frequently in Japanese
POAG patients than in controls
21 and the C-1000G poly-
morphism, also designated as MYOC.mt1, was reported to be
related to the severity of POAG.
22 23 However, the former
polymorphism has never been identiﬁed in other races and the
C-1000G polymorphism appeared to be of no value in the
evaluation of patients with glaucoma in ensuing studies.
92 42 5It
appears that a predisposition to glaucoma related to MYOC is
mediated through structural gene alterations, but not by non-
coding sequence variants such as promoter sequence variants.
Studies on transgenic mice showed that mice overexpressing
MYOC at a level similar to that induced by steroid use did not
Table 1 Genotype distributions and allele frequencies of (GT)n repeat
markers in the 59-ﬂanking region of MYOC in glaucoma patients and
normal controls
Genotype distribution Allele frequency
n 13/13 13/14 13/15 14/15 14/14 15/15 13 14 15
Control 74 20 15 32 2 5 0 0.588 0.115 0.297
POAG 60 24 9 18 3 5 1 0.625 0.117 0.258
NTG 47 25 3 14 0 4 1 0.713 0.053 0.234
SIG 61 29 1 24 2 5 0 0.680 0.025 0.295
POAG, primary open-angle glaucoma; NTG, normal tension glaucoma; SIG, steroid-induced
glaucoma.
Table 2 Genotype distributions and allele frequencies of polymorphic variants in the 59-ﬂanking region of
MYOC in glaucoma patients and normal controls
G-38A T-224C G-306T
Genotype
distribution
Allele
frequency
Genotype
distribution of
Allele
frequency
Genotype
distribution of
Allele
frequency
n G GG AA AG A T TT CC C T C G GG TT TT C
Control 74 63 11 0 0.926 0.074 16 38 20 0.473 0.527 60 13 1 0.899 0.101
POAG 60 51 9 0 0.925 0.075 11 24 025 0.383 0.617 52 7 1 0.925 0.075
NTG 47 45 1 1 0.968 0.032 7 22 18 0.383 0.617 40 7 0 0.926 0.074
SIG 61 56 3 2 0.943 0.057 7 34 20 0.393 0.607 47 13 1 0.877 0.123
POAG, primary open-angle glaucoma; NTG, normal tension glaucoma; SIG, steroid-induced glaucoma.
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Laboratory sciencedevelop elevated IOP or glaucoma,
78suggesting that increased
MYOC expression alone is not sufﬁcient to cause glaucoma. If
the level of MYOC is not important in determining the glau-
coma phenotype, it is likely that any promoter sequence variant
is not directly involved in the development of OAG. This could
be an explanation for the lack of association between our
markers and OAG. Several genes were mapped to GLC1A but
excluded as candidates for OAG by genetic linkage analysis.
1
Therefore, we do not believe that our SNPs are under linkage
disequilibrium with other genes that may be responsible for the
development of glaucoma.
In summary, we investigated whether MYOC induction can
lead to IOP elevation or vice versa and if any MYOC promoter
variant is associated with OAG. We showed that MYOC
expression in vitro was neither correlated with elevated IOP in
vivo nor induced by hydrostatic pressure mimicking elevated
IOP. We also showed that the MYOC gene itself is not associated
with OAG, including POAG, NTG and SIG. Therefore, our
results do not support the hypothesis that MYOC induction
might be linked to IOP variation and that promoter variants of
MYOC could be a risk factor for the pathogenesis of OAG.
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